Delve into Vandria's technology and its Alzheimer's candidate, VNA-318, the first mitophagy-based candidate in Alzheimer's in ...

While non-exhaustive, this list offers an overview of the year’s biotech events taking place around the world, aimed at partnering and connecting with decision makers in biopharma. If there is a ...

A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.

Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics.

Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...

Synthetic biology (SynBio) has stopped dividing itself by categories — red, yellow, green, blue, white — medicine, environment, agriculture, water, and industry —and is now united as one movement, ...

Mapping how T-cell leukemia develops, a team of researchers at the Wellcome Sanger Institute, Great Ormond Street Hospital, University College London, and Addenbrooke’s Hospital in the U.K. identified ...

If you thought September was huge for M&As in the biopharma space, you didn’t see October coming. Nine major M&As were signed, with most of them being multi-billion-dollar deals in various therapeutic ...

The global biotech industry is booming, and by 2025 it will reach an estimated market worth of $729B. But while great innovation is driven by emerging biotechs, these companies often lack resources, ...

Recombinant protein expression lies at the heart of modern biotechnology and biopharmaceutical production. For decades, the field has relied primarily on two established expression systems namely ...